4D Molecular Therapeutics In
Late-stage biotech 4D Molecular develops synthetic AAV vectors via its proprietary Therapeutic Vector Evolution platform. Lead 4D‑150 delivers anti‑VEGF for wet AMD and diabetic macular edema; early 4D‑710 targets cystic fibrosis. Partnerships with Astellas, Arbor, uniQure grow.
Headquarters: United States (USA)
- Website: Visit Site 🔗
- Type: Corporation
Company Profile
- Sector: Professional Services
- Industry: Biotechnology Research
- Employees: 227
- HQ: EmeryVille
Unlock the full potential.
Upgrade
Get access to Relative P/E Ratio Valuation Histogram.